Geode Capital Management, LLC Apellis Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,787,917 shares of APLS stock, worth $51.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,787,917

Previous 1,689,890 5.8%

Holding current value

$51.4 Million

Previous $99.3 Million 30.95%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$38.07 - $59.71 $3.73 Million - $5.85 Million	98,027 Added 5.8%	1,787,917 $68.6 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $3.28 Million - $4.29 Million	59,248 Added 3.63%	1,689,890 $99.3 Million
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $2.82 Million - $4.91 Million	75,816 Added 4.88%	1,630,642 $97.6 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.33 Million - $5.04 Million	56,437 Added 3.77%	1,554,826 $59.1 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $26.1 Million - $31.7 Million	-339,890 Reduced 18.49%	1,498,389 $137 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $4.11 Million - $5.91 Million	88,278 Added 5.04%	1,838,279 $121 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $2.54 Million - $3.59 Million	58,799 Added 3.48%	1,750,001 $90.5 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3.63 Million - $5.65 Million	81,040 Added 5.03%	1,691,202 $116 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $4.09 Million - $6.91 Million	116,642 Added 7.81%	1,610,162 $72.8 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $4.99 Million - $7.61 Million	140,691 Added 10.4%	1,493,520 $75.9 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $5.05 Million - $8.08 Million	164,437 Added 13.84%	1,352,829 $64 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $2.21 Million - $4.91 Million	70,257 Added 6.28%	1,188,392 $39.2 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $2.91 Million - $4.62 Million	71,222 Added 6.8%	1,118,135 $70.7 Million
Q1 2021 May 12, 2021	BUY	$40.8 - $57.39 $4.5 Million - $6.33 Million	110,380 Added 11.79%	1,046,913 $44.9 Million
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $1.81 Million - $3.36 Million	58,719 Added 6.69%	936,533 $53.6 Million
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $308,505 - $400,973	11,916 Added 1.38%	877,814 $26.5 Million
Q2 2020 Aug 13, 2020	BUY	$24.8 - $38.49 $938,655 - $1.46 Million	37,849 Added 4.57%	865,898 $28.3 Million
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $3.05 Million - $7.54 Million	170,112 Added 25.86%	828,049 $22.2 Million
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $689,232 - $960,559	31,187 Added 4.98%	657,937 $20.1 Million
Q3 2019 Nov 12, 2019	BUY	$24.09 - $32.18 $1.17 Million - $1.57 Million	48,753 Added 8.43%	626,750 $15.1 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $1.63 Million - $2.29 Million	90,565 Added 18.58%	577,997 $14.6 Million
Q1 2019 May 14, 2019	BUY	$12.81 - $19.82 $840,118 - $1.3 Million	65,583 Added 15.55%	487,432 $9.5 Million
Q4 2018 Feb 13, 2019	BUY	$11.47 - $18.71 $557,476 - $909,362	48,603 Added 13.02%	421,849 $5.56 Million
Q3 2018 Nov 13, 2018	BUY	$16.57 - $21.03 $216,139 - $274,315	13,044 Added 3.62%	373,246 $6.64 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $4.13 Million - $6.31 Million	210,210 Added 140.15%	360,202 $7.92 Million
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $53,195 - $98,797	3,797 Added 2.6%	149,992 $3.32 Million
Q4 2017 Feb 13, 2018	BUY	$12.71 - $21.7 $1.86 Million - $3.17 Million	146,195	146,195 $3.17 Million

Others Institutions Holding APLS

# of Institutions

301

Shares Held

114M

Call Options Held

5.21M

Put Options Held

691K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.16B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Apellis Pharmaceuticals, Inc. Transaction History